Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Antiviral Res. 2017 Nov 10;149:48–57. doi: 10.1016/j.antiviral.2017.11.007

Fig. 6. Immunization with preS VLP induces robust anti-preS antibodies and T cell responses in HBV transgenic mice.

Fig. 6.

HBV transgenic mice were immunized intramuscularly with preS VLP (n = 6) or PBS (n = 6). (A) Time schedule for preS VLP as a vaccine to treat HBV transgenic mice. (B–D) The serum anti-preS titers were determined by ELISA. The plates were coated with 1 μg/mL purified recombinant preS. The immunization condition is labeled next to chart color codes. The sera were diluted by 100 folds in all the assays. CD8+ T cells (E) or CD4+ T cells (F) were gated, and IFN-γ-producing cells are presented as the percent average from each group. (G) On day 70, splenocytes were isolated and analyzed for IFN-γ expression by ELISPOT assays. ELISPOT experiments were performed in triplicate wells per condition. (H) Representative images of ELISPOT from each group are shown. All values are presented as the average from each group, and error bars indicate ± SEM.